BCM
TCRT icon

BlueCrest Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

BlueCrest Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-122
Closed -$78K – 574
2019
Q3 		$78K Buy
+122
New +$96.8K 0.01% 537
2019
Q2 		– Sell
-157
Closed -$91K – 988
2019
Q1 		$91K Buy
+157
New +$65.6K ﹤0.01% 1088
2018
Q4 		– Sell
-82
Closed -$39K – 1391
2018
Q3 		$39K Buy
82
+12
+17% +$5.14K ﹤0.01% 1454
2018
Q2 		$32K Buy
+70
New +$44.4K ﹤0.01% 1443

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlueCrest Capital Management's TCRT Position: Q4 2019 in Review

BlueCrest Capital Management sold out of Alaunos Therapeutics (TCRT) in Q4 2019, closing a stake of 122 shares — an estimated $78K sold.

BlueCrest Capital Management first reported a position in TCRT in Q2 2018 and held it in 4 quarters. The position peaked at $91K in Q1 2019. 148 funds tracked by Wall St. Rank hold TCRT as of Q4 2019.

  • BlueCrest Capital Management reported no remaining Alaunos Therapeutics position as of Q4 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 122 Alaunos Therapeutics shares in Q4 2019, an estimated $78K.
  • BlueCrest Capital Management first reported a position in Alaunos Therapeutics in Q2 2018 and held it in 4 quarters.
  • BlueCrest Capital Management's Alaunos Therapeutics position peaked at $91K in Q1 2019.
  • 148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.